Trial Profile
Ertapenem versus imipenem or meropenem in critically ill patients with infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Sep 2015
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary) ; Imipenem; Meropenem
- Indications Enterobacteriaceae infections
- Focus Therapeutic Use
- 08 Sep 2015 New trial record